Summary

Results from a 48-week, open-label extension of A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla [SINGLE, NCT01263015], a phase 3, randomized, double-blind trial, have reaffirmed week 48 and week 96 results [Walmsley SL et al. N Engl J Med. 2013] of the superiority of once-daily dolutegravir 50 mg used with abacavir/lamivudine compared with efavirenz/tenofovir/emtricitabine in treatment-naïve patients with HIV-1.